iOnctura Extends Series A to EUR 20.1M

3B Future Health Fund Joins Blue Chip Investor Syndicate Accelerate Development of Next Generation Molecules Targeting Cancer and Fibrosis

Geneva, Switzerland, 14 July 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, today announces that it has raised an additional EUR 5.1 million bringing the total Series A financing to EUR 20.1 million. New investor 3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR joins the existing blue chip investor syndicate of M Ventures, INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...